A double-blind comparison of clonazepam and lorazepam was conducted in 24 patients with acute mania. Patients received either clonazepam or lorazepam alone for 14 days. Treatment with lorazepam produced marked improvement in symptomatology, while treatment with clonazepam failed to demonstrate a significant therapeutic effect. Sixty-one percent of patients responded to treatment with lorazepam, with 38.5% achieving remission. This compares to an 18.2% response rate and 0% remission rate in patients treated with clonazepam. These findings support the usefulness of lorazepam in the treatment of acute mania.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00004714-199010060-00004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polypharmacy and anticholinergic burden scales in older adults: a cross-sectional study among psychiatric outpatients in a tertiary care hospital.
BMC Geriatr
January 2025
Department of Orthopaedics, Kasturba Medical College, Manipal, Karnataka, 576104, India.
Introduction: Mental disorders are prevalent among older adults, often leading to the use of multiple medications, many with anticholinergic properties. Polypharmacy, common in this population, is a major contributor to anticholinergic burden, which is linked to cognitive and physical decline. This study investigates the relationship between polypharmacy and anticholinergic burden across seven anticholinergic burden scales in elderly patients attending the psychiatric outpatient.
View Article and Find Full Text PDFMaintenance treatment of catatonia with benzodiazepines: A case series and literature review.
Neuropsychopharmacol Hung
December 2024
College of Medicine, University of Kentucky, Lexington, KY 40506, USA.
Objective: Benzodiazepines, particularly lorazepam, are good options for acute catatonia treatment. Published catatonia literature on benzodiazepine maintenance treatment and benzodiazepine tolerance is limited.
Methods: This is a chart review covering 30 years of clinical experience in the state of Kentucky, (United States of America), where there was no easy access to electroconvulsive therapy.
Clozapine-induced acute akathisia: A case report.
J Family Med Prim Care
September 2024
Department of Neurology, Christian Medical College and Hospital, Ludhiana, Punjab, India.
Existing data suggest that clozapine has lesser propensity of developing akathisia as compared to first general antipsychotics. Clozapine is mostly used in patients with treatment-resistant schizophrenia, which is a second-generation antipsychotic. Akathisia is one of the rare side effects of clozapine.
View Article and Find Full Text PDFMasked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial.
JAMA Intern Med
December 2024
Geriatric, Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California.
Article Synopsis
- Placebo effects are often seen in clinical trials for benzodiazepine receptor agonists, leading to recommendations for discontinuation of these medications in older adults and the use of cognitive behavioral therapy for insomnia (CBTI) instead.
- This study aims to compare the effects of a masked tapering process combined with enhanced CBTI against standard CBTI with an unmasked taper in helping older adults discontinue benzodiazepine receptor agonists.
- The primary outcome measured is the percentage of participants successfully discontinuing their medication after 6 months, with additional assessments of insomnia severity and short-term discontinuation rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!